Abstract

Glucagon-like peptide 1 (GLP-1) is an intestinal hormone that is secreted after meals and augments insulin secretion in response to absorbed glucose. Experiments in animals have demonstrated that GLP-1 is necessary for normal glucose tolerance. GLP-1 is effective in lowering blood glucose levels in persons with diabetes by increasing insulin secretion, and by suppressing glucagon release, delaying gastric emptying, and possibly other mechanisms as well. Recent studies investigating a potential role for decreased GLP-1 secretion in the glucose intolerance of aging have been inconclusive. However, ongoing research on the therapeutic application of GLP-1 is promising, and GLP-1 or GLP-1 receptor agonists may provide a novel means of treating diabetes and glucose intolerance in the future.

Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.